Distribution and licensing of drug discovery tools--NIH perspectives.
Now, more than ever, drug discovery conducted at industrial or academic facilities requires rapid access to state-of-the-art research tools. Unreasonable restrictions or delays in the distribution or use of such tools can stifle new discoveries, thus limiting the development of future biomedical products. In grants and its own research programs the National Institutes of Health (NIH) is implementing its new policy to facilitate the exchanges of these tools for research discoveries and product development.
Ferguson
Steven M
SM
Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852, USA. sf8h@nih.gov
Kim
J P
JP
D000818:Animals; D017408:Guidelines as Topic; D006801:Humans; D008004:Licensure / Q000331:legislation & jurisprudence* / Q000639:trends; D009316:National Institutes of Health (U.S.) / Q000331:legislation & jurisprudence*; D012106:Research / Q000295:instrumentation / Q000331:legislation & jurisprudence / Q000639:trends; D012107:Research Design; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence*; D014481:United States; D014492:United States Public Health Service